Literature DB >> 32353489

The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease.

Alison J Dicker1, Jeffrey T J Huang1, Mike Lonergan1, Holly R Keir1, Christopher J Fong1, Brandon Tan1, Andrew J Cassidy1, Simon Finch1, Hana Mullerova2, Bruce E Miller2, Ruth Tal-Singer2, James D Chalmers3.   

Abstract

BACKGROUND: The sputum microbiome has a potential role in disease phenotyping and risk stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal cohort studies exist.
OBJECTIVE: Our aim was to investigate the COPD sputum microbiome and its association with inflammatory phenotypes and mortality.
METHODS: 16S ribosomal RNA gene sequencing was performed on sputum from 253 clinically stable COPD patients (4-year median follow-up). Samples were classified as Proteobacteria or Firmicutes (phylum level) and Haemophilus or Streptococcus (genus level) dominant. Alpha diversity was measured by using Shannon-Wiener diversity and Berger-Parker dominance indices. Survival was modeled by using Cox proportional hazards regression. A subset of 78 patients had label-free liquid chromatography with tandem mass spectrometry performed, with partial least square discriminant analysis integrating clinical, microbiome, and proteomics data.
RESULTS: Proteobacteria dominance and lower diversity was associated with more severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease classification system (P = .0015), more frequent exacerbations (P = .0042), blood eosinophil level less than or equal to 100 cells/μL (P < .0001), and lower FEV1 (P = .026). Blood eosinophil counts showed a positive relationship with percent of Firmicutes and Streptococcus and a negative association with percent Proteobacteria and Haemophilus. Proteobacteria dominance was associated with increased mortality compared with Firmicutes-dominated or balanced microbiome profiles (hazard ratio = 2.58; 95% CI = 1.43-4.66; P = .0017 and hazard ratio = 7.47; 95% CI = 1.02-54.86; P = .048, respectively). Integrated omics analysis showed significant associations between Proteobacteria dominance and the neutrophil activation pathway in sputum.
CONCLUSION: The sputum microbiome is associated with clinical and inflammatory phenotypes in COPD. Reduced microbiome diversity, associated with Proteobacteria (predominantly Haemophilus) dominance, is associated with neutrophil-associated protein profiles and an increased risk of mortality.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COPD; Haemophilus; Microbiome; eosinophil; phenotype

Mesh:

Year:  2020        PMID: 32353489     DOI: 10.1016/j.jaci.2020.02.040

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  22 in total

Review 1.  Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.

Authors:  Claire Healy; Natalia Munoz-Wolf; Janné Strydom; Lynne Faherty; Niamh C Williams; Sarah Kenny; Seamas C Donnelly; Suzanne M Cloonan
Journal:  Respir Res       Date:  2021-04-29

Review 2.  Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 - changing paradigms?

Authors:  Zoran Stojanovic; Filipe Gonçalves-Carvalho; Alicia Marín; Jorge Abad Capa; Jose Domínguez; Irene Latorre; Alicia Lacoma; Cristina Prat-Aymerich
Journal:  ERJ Open Res       Date:  2022-09-12

Review 3.  Impact of Lung Microbiota on COPD.

Authors:  Cristina Russo; Valeria Colaianni; Giuseppe Ielo; Maria Stella Valle; Lucia Spicuzza; Lucia Malaguarnera
Journal:  Biomedicines       Date:  2022-06-06

Review 4.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

5.  Extended Bacteria Culture-Based Clustering Identifies a Phenotype Associating Increased Cough and Enterobacterales in Stable Chronic Obstructive Pulmonary Disease.

Authors:  Anaëlle Muggeo; Jeanne-Marie Perotin; Audrey Brisebarre; Sandra Dury; Valérian Dormoy; Claire Launois; Julien Ancel; Pauline Mulette; Christophe de Champs; Gaëtan Deslée; Thomas Guillard
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

Review 6.  Precision medicine in bronchiectasis.

Authors:  Thomas Pembridge; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2021-12

7.  The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review.

Authors:  Zhiping Xu; Lingxia Zhu; Jingye Zhan; Lijun Liu
Journal:  Eur J Med Res       Date:  2021-10-14       Impact factor: 2.175

8.  A Refined View of Airway Microbiome in Chronic Obstructive Pulmonary Disease at Species and Strain-Levels.

Authors:  Zhang Wang; Haiyue Liu; Fengyan Wang; Yuqiong Yang; Xiaojuan Wang; Boxuan Chen; Martin R Stampfli; Hongwei Zhou; Wensheng Shu; Christopher E Brightling; Zhenyu Liang; Rongchang Chen
Journal:  Front Microbiol       Date:  2020-07-30       Impact factor: 5.640

Review 9.  Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Authors:  Kiki Waeijen-Smit; Sarah Houben-Wilke; Antonio DiGiandomenico; Ulf Gehrmann; Frits M E Franssen
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

10.  Phenotyping acute exacerbation of COPD: what more can we do for hospitalised patients?

Authors:  Lai-Jian Cen; Xiao-Xian Zhang; Wei-Jie Guan
Journal:  ERJ Open Res       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.